Leadership Profiles

Tetra Bio-Pharma’s executive team, board of directors, and advisory committee are recognized experts in their respective fields including drug development, regulatory affairs, clinical research, intellectual property, marketing and medical affairs.

Together, the company’s leadership team provides an extensive background to support Tetra Bio-Pharma’s long-term vision to offer a diverse portfolio of cannabinoid-derived drugs to address unmet medical needs.


Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, is a drug development specialist with 25 years experience in the pharmaceutical industry. Having obtained a Master’s of Science and Doctorate (PhD) degree in biomedical sciences, he has developed an expertise in drug safety and regulatory affairs while working in the pharmaceutical and biotechnology industries. He has specific expertise in the development of drug-device combination products, biologics, and botanical medicines.

Dr. Chamberland has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Regulatory Officer since October 15, 2018. He is responsible for the transformation of the biotechnology company into a pharmaceutical firm that discovers, develops and commercializes cannabinoid-based pharmaceuticals. The mandate began with a company of less than 10 employees and today has over 50 employees specialized in regulatory affairs, clinical research, manufacturing compliance, clinical trial product manufacturing, clinical operations and research and development. Dr. Chamberland oversees the scientific and regulatory requirements for drug and medical device approval (i.e., vaporizers) and strategic planning for corporate development.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM).  He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Dr. Chamberland is a pioneer in drug-device combination products. He developed and executed the regulatory strategy for two novel products and obtained marketing approval. In 2002, he was invited by the FDA to present at the FDA Public Hearing to regulate combination products. He spent 7-years as a member of the Scientific Advisory Committee of a Venture Capital fund and 6-years on a Health Canada Expert Committee. He was also employed by the Victhom Laboratory; Angiogene Inc.; CATO Research Ltd; and MDS Pharma, respectively.

Before joining Tetra Bio-Pharma, Mr. Boily served as Vice-President and Financial Officer at Acasti Pharma Inc., a dual-listed (TSX-V & Nasdaq)  biopharmaceutical innovator focused on the research and development of prescription drugs using Omega-3 fatty acids derived from krill oil for treatment of hypertriglyceridemia. He raised C$50M to fund the Trilogy Phase 3 program and later set-up an “at-the-market” (or ATM) program for aggregate proceeds of up to US$ 30M with sales on Nasdaq. He also migrated financial reporting to US-Gaaps to become a fully compliant SEC registrant and filed a registration statement on Form S-3 with the SEC to register up to US$200 million of common shares, warrants and units. 

Prior to Acasti, Mr. Boily served as a Director of Finance & Information Technology at Innovaderm Research Inc., a North American contract research organization (CRO) specialized in dermatology. Working closely with the President and founder, Mr. Boily undertook a vast financial, IT and growth mandate and increased revenues and profits over 25%.

Formerly, Mr. Boily was a Director of Finance at Teva Canada Innovation where he oversaw and reported on the financial conduct of all clinical R&D activities and managing branded product launches in the therapeutic areas of central nervous system (CNS), respiratory, oncology and pain care.  

Mr. Boily holds a Bachelor’s of Science in Accounting from HEC Montreal and is a Quebec-Chartered Public Accountant (CPA).

Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

Mr. Néron holds a Bachelor’s degree in Business Administration (BBA) in Marketing from Université du Québec in Chicoutimi (QC).

Melanie Kelly is a Professor in Pharmacology and Ophtamology at Dalhousie University in Halifax with expertise in preclinical and clinical research design, novel drug development, medical cannabis and cannabinoid based drugs.

A respected research professional with a Doctor of Philosophy (PhD) focused on drug discovery and molecular pharmacology, Dr. Kelly has significant research experience in the field of G protein coupled receptors and endocannabinoid/cannabinoid signaling. She is considered to be an expert in the cannabinoid drug development space.

Her primary research expertise is pharmacology, specifically receptors and cell signaling pathways. Her work has examined pathways important to the survival of retinal ganglion cells in experimental models of glaucoma and has made us of gene mutations, to explore signaling pathways involved in retinal progenitor cell growth and development. Dr. Kelly’s current research addresses the pharmacology of the endocannabinoids and lipid signaling in the mammalian eye, with a specific focus on the regulation of intraocular pressure and interactions between glial cells and microvasculature in the regulation of retinal blood flow.

She is a member of the International Cannabis Research Society.

 Dr. Graham Wood joined Tetra Bio-Pharma in September 2020 as Chief Operating Officer, to lead the regulated drug development activities. Dr. Wood has over twenty years of drug development experience. Most recently he was Chief Scientific Officer at Neptune Wellness, where he leads product development and clinical research activities. Prior to that, he was Chief R&D Officer at Altasciences where he was responsible for developing innovative nonclinical and clinical techniques and overseeing the clinical pharmacology study designs. He was also Chief Executive Officer at Manna Research, which he grew from a single clinical research site to the largest family practice site network in Canada. As President at Cetero Research, he was responsible for the early and late stage clinical development conducted at the Cetero facilities in Toronto and Miami. He holds a PhD in Neurology and Neurosurgery from McGill University and worked as Fellow at the National Institute of Health


Dr. De Pauw is responsible for clinical operations and relations with the medical community with a view to building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She also directs the Company’s public education initiatives to build and increase awareness about the benefits and adverse effects of cannabis-cased treatment.

Aurelia holds a master’s degree and PhD in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium. She followed this with a five-year post-doctoral position in the field of stem cell therapy. After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.

Ms. Doran is a board-certified toxicologist with over 18 years of experience in the pharmaceutical, biotechnology, and medical device industries, including overall program management of global product registrations.  She has a broad range of experience in evaluating the toxicology and safety of products being registered and used in the global market.  Ms. Doran has a unique background in preclinical program management and very strong scientific expertise that she gained in her roles in the medical device, biotechnology industry as well as in consulting to clients in pharmaceutical, natural health and consumer product, and cosmetics industries.  She has been accountable for the full scope of drug development programs (including regulatory strategy, R&D, and clinical testing) and is thus thoroughly versed in all aspects of lifecycle management for pharmaceutics and products of biotechnology.

As a consultant to the industry for several years, Ms. Doran provided expert advice in the area of product development, including strategic advice, gap analyses, program planning, and program management for novel compounds as well as second-generation products.  She has extensive experience with designing, implementing, and critically evaluating IND-enabling programs as well as review and preparation of regulatory packages for new device and drug submissions. 

Ms. Doran holds a Bachelor’s of Science from Western University [formerly University of Western Ontario] in Pharmacology and Toxicology and a Master’s of Science from Purdue University in Medicinal Chemistry and Molecular Pharmacology.  Ms. Doran is a Diplomat of the American Board of Toxicology and is as a European Registered Toxicologist with the Institute of Biology & British Toxicology Society (London, United Kingdom).

Prior to joining Tetra Bio-Pharma Team, Dania worked as Director of Pharmacy at Canopy Growth Corporation where she led the Canadian strategy and tactical plans for Retail & Hospital Pharmacy including pharmacy education, business development, public affairs initiatives, key opinion leaders and key accounts management (2017-2020). Dania worked on the cannabis file at Shoppers Drug Mart (2015-2017) where she led and supported launch initiatives within the cannabis space including pharmacy education, strategy, marketing, and medical cannabis operationalization.

Dania assumed diversified leadership roles within the pharmaceutical industry, in sales management, marketing, and medical functions at companies including GlaxoSmithKline, Procter & Gamble Pharma, Roche and Eisai (1998-2015). She contributed to the growth and launch of several pharmaceutical products in varied therapeutic areas in the Middle East/North Africa (MENA) region and Canada.

Over the last five years, Dania has developed a unique skill set that includes cannabinoid education, commercialization, and business development within the cannabis space. She led the training of thousands of Canadian pharmacists on all aspects of cannabinoids. This experience combined with her interest in cannabinoid medicine and polypharmacy reduction was a key asset for joining Tetra.

Mrs. Scott holds a Bachelor of Science in Biology and a Bachelor of Science in Pharmacy, both from Lebanese American University in Lebanon.

Mr. Ofer Yifrach-Stav has extensive experience in the pharmaceutical and medical device industries where he worked with leading companies in North America, Europe and Asia.  During this time, he successfully led the process to prepare these companies for Quality Assurance Audits by Health Canada, the U.S. Food and Drug Administration (FDA), the EU and the Israeli Ministry of Health.  Over the years he developed expertise in production process validations and other areas of quality assurance. As part of Tetra Bio-Pharma’s Management Team, Ofer is responsible for the scale-up activities of our lead products and for ensuring our readiness for the submission of NDS/NDA. Ofer holds a master’s degree in Environmental Engineering, which he graduated with honours. He also holds a bachelor’s degree in Biotechnology Engineering from Ben-Gurion University of the Negev, in Israel.


Dr. Cheliak is the CEO of Panag Pharma, a Canadian biotech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of business experience in a wide variety of biotechnology fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. In addition to having held executive positions in the public sector, he has extensive deal-making experience within the pharmaceutical industry, academic institutions and research hospitals including securing financing with both big and small pharma. He currently serves as a Director of Solarvest (SVS) and is Vice Chair of the Government of Canada’s Networks Centres of Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in Genetics from the University of Alberta.

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Scientific Officer since October 15, 2018. He held the positions of Interim Chief Executive Officer and Chief Scientific Officer respectively since April 2018 and June 2016. Dr. Chamberland’s extensive experience in both executive and scientific roles establish him as an expert in the biopharmaceutical space. Dr. Chamberland has more than two decades of experience in drug development for the North American pharmaceutical industry with specific expertise in regulatory affairs, and the development and management of clinical research protocols and clinical studies for botanical medicines. He was also a member of the investment committee of the venture capital fund, Fonds Bionovation, for 7 years.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM).  He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Mr. Merton has over 20 years of financial and business experience, including 10 years as CFO for public companies involved in the capital markets. Following 12 years with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance specialist. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. Since assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In this role, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”).

Dr. Brent Norton holds his medical doctorate degree from McGill University, an MBA from Ivey Business School at Western University and was granted the ICD.D designation by the Institute of Corporate Directors following the completion of the Directors Education Program at the Rotman School of Business in Toronto. With over 25 years of experience in the life sciences industry, Dr. Norton has used his cross-functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer and others, and taken products through the FDA to global out-licensing with Johnson & Johnson. His contributions to  five companies have allowed early investors the opportunity to crystallize investment gains of over $2.5B. Brent is currently a Venture Partner with Lumira Ventures and has recently been appointed as a member of the prestigious Association of Faculties of Medicine of Canada.

Dale Weil brings close to 35 years of business development experience, much of which was acquired while working at McKesson Canada, a diversified healthcare company and the largest pharmaceutical distributor in the country. At McKesson Canada, Ms. Weil held various leadership positions, most recently as Senior Advisor to the President. Ms. Weil holds a Bachelor’s degree in Marine Biology and a Master’s degree in Business Administration, both from McGill University. Additionally, Dale received the ICD.D designation from the Institute of Corporate Directors. The ICD.D designation represents a lifelong commitment to excellence in the boardroom, a desire to stay current, and to be a more effective director. In January 2020, Dale was appointed as the Executive Director of the West Island Palliative Care Centre, an initiative that she has been involved with since 2010.